The paucity of evidences about the long-term durability of currently available transcatheter prostheses is one of the main issues of transcatheter aortic valve implantation (TAVI). We sought to assess 3-year clinical and echocardiographic outcomes of patients undergoing TAVI with the third generation CoreValve prosthesis (Medtronic Incorporation, MN, USA).
Introduction
Transcatheter aortic valve implantation (TAVI) is an emerging, catheter-based technology that allows for implantation of a prosthetic valve without open heart surgery for the treatment of severe aortic stenosis (AS). 1 The recently published Placement of Aortic Trans Catheter Valves (PARTNER) randomized controlled trial cohort B demonstrated that TAVI remarkably reduced the mortality, when compared with standard therapy, in patients not suitable candidates for surgery. 2 In addition, PARTNER cohort A results showed that 1-year outcomes after TAVI compare favourably with surgical aortic valve replacement. 3 While a number of large single-arm registries demonstrated encouraging short and mid-term effectiveness of TAVI, 4 -9 there is a paucity of data on benefits of this technique at longer followup. 10, 11 The lack of evidences for the long-term durability of currently available transcatheter heart valves is one of the main issue which prevents TAVI to be used in younger and lower risk patients. The aim of this multicentre study was to assess 3-year clinical and echocardiographic outcomes in patients undergoing TAVI with the third generation (18-Fr) CoreValve prosthesis (CRS) (Medtronic Incorporation, MN, USA).
Methods Study design and patient population
Consecutive patients undergoing TAVI with the 18-Fr CRS at 12 centres across Italy and enrolled prospectively in a dedicated webbased database from June 2007 to August 2008 formed the study population. Patient eligibility criteria, registry design, features of the third generation CRS, and technical details of the procedure have been described elsewhere. 7, 12, 13 Briefly, the principal investigators of the first four centres who began CoreValve implantation in Italy (C.T., G.T., A.S.P., F.E.) designed the study as part of their role on the steering committee, in collaboration with the sponsor, Endotech (CO, Italy). The sponsor financed the web-based database and was involved in collection, source verification, and quality control of the data, with oversight by an independent clinical events committee. All patients had severe symptomatic AS with valve area ,1 cm 2 . Eligibility for TAVI was established at each centre based on the consensus of a local multidisciplinary team, including clinical cardiologists, cardiac surgeons, and cardiac anaesthesiologists.
14 All the procedures were approved for compassionate use in patients considered at high risk for surgery, according to accepted inclusion and exclusion criteria. 15 Written informed consent was obtained in all cases. Clinical follow-up was planned at 1, 3, 6, and 12 months and then yearly with visits or telephone contacts. Echocardiographic follow-up was not mandatory, but recommended at 1, 3, 6, and 12 months and then yearly.
Definitions
Device success, cardiovascular death, peri-procedural and spontaneous myocardial infarction, strokes, bleedings, combined safety and efficacy endpoints, and echocardiographic criteria post-TAVI were defined according to the Valve Academic Research Consortium (VARC). 16 All major neurological events were adjudicated by the cardiologist, anaesthesiologist, and specialized radiologist with the aid of computed tomography imaging.
Statistical analysis
Continuous variables were analysed for a normal distribution with the Shapiro-Wilk test. Continuous variables following a normal distribution are presented as mean + standard deviations and were compared using repeated measures ANOVA for within-group comparisons. Variables not following a normal distribution are expressed as median (IQR). Categorical variables are presented as counts and percentages. The cumulative incidences of clinical events at follow-up were assessed with the Kaplan-Meier method, and the log-rank test was used for comparison between patients with renal insufficiency and those experiencing bleeding and the rest of the study population. All data were processed using the Statistical Package for Social Sciences, version 15 (SPSS, Chicago, IL, USA). The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agreed to the manuscript as written.
Results
Among all patients comprised in the registry, 181 eligible for 3-year follow-up formed the study cohort. Baseline demographic, clinical and echocardiographic variables of these patients are presented in Table 2 .
3-year clinical outcomes
Clinical follow-up was available in 178 patients (98.3%) at a mean of 41 + 3 months (range 36 -51 months) after TAVI. All-cause mortality rates at 1, 2, and 3 years were 23.6, 30.3, and 34.8%, respectively ( Figure 1A ). Cardiovascular mortality rates at 1, 2, and 3 years were 11.2, 12.1, and 13.5%, respectively ( Figure 1B ). As showed in the Table 3 , a total of 67 (37.0%) patients died during the follow up period and the majority of deaths were not related to cardiovascular events. Cardiovascular death occurred at a median of 1.2 months (IQR 0.8 -9.2) and non cardiovascular death occurred at a median of 11.6 months (IQR 2.5 -25.1).
Rates of VARC-defined neurologic events, acute kidney injury, myocardial infarction, bleedings and hospitalization due to cardiac reasons are listed in the Table 4 . Patients experiencing an in-hospital admission due to cardiac causes at 3-years had moderate to severe mitral regurgitation in 52% or systolic pulmonary artery pressure .60 mmHg in 44% of cases.
The actuarial rate of a composite of death, major stroke, myocardial infarction and life-threatening bleeding was 30.1% at 1 year, 36.5% at 2 years, and 40.3% at 3 years ( Figure 1C) . Overall, the VARC-defined combined efficacy endpoint at 3-years was achieved in 59 patients among the 158 who were alive at 30-day (57.3%). Rates of major stroke and bleedings (including lifethreatening and major bleedings) were 2.8 and 20.4% at 30 days and 3.9 and 22.1% at 3 years. Figure 2 shows the Kaplan-Meier curves for mortality stratified by the presence of renal insufficiency and post-procedural bleedings (including life-threatening and major bleedings). Patients with renal insufficiency did not present significant differences in term of 30-day mortality (3.8 vs. 7.8%; P ¼ 0.332) compared with those without, whereas they had higher mortality at 3-year follow-up (51. Post-dilatation, n (%) 18 (9.9)
Reposition with snaring, n (%) TAVI: long-term follow-up other hand, patients experiencing post-procedural major or lifethreatening bleeding had a higher rate of mortality already at 30 days (21.6 vs. 2.8%; P , 0.001) and this result was sustained at 3-year follow-up (62.2 vs. 28.4%; P , 0.001). NYHA class 3/4 at 1-year was virtually absent in the study population (6%). This benefit was sustained at 2-and 3-year. (Figure 3) .
3-year prosthesis performance
Echocardiographic follow-up was available for 89 of 119 patients (78.1%) who were alive at 3 years. Mean pressure gradients decreased from 52.2 + 18.1 mmHg (pre-TAVI) to 10.3 + 3.1 mmHg (1 year post-TAVI) (P , 0.001); AVA increased from 0.6 + 0.2 cm 2 (pre-TAVI) to 1.8 + 0.4 cm 2 (1-year post-TAVI); these results remained stable over the 3 years of follow-up ( Figure 4) . Paravalvular leak was observed in the majority of patients. Mostly, it was trace to mild in at each time point (48.1, 50.3, and 47.2% at 1, 2, and 3 years, respectively); in detail, moderate paravalvular leak was observed in 17.8, 16.5, and 10.1% of patients at 1, 2, and 3 years, respectively ( Table 5 ). All patients with mild paravalvular leak were either unchanged or improved over time. There were no cases of progression to moderate or severe regurgitation. No cases of structural valve deterioration were observed.
Discussion
The introduction of TAVI for treatment of severe AS has expanded the therapeutic possibilities for successfully managing severe AS. Although large registries and randomized trials have proved the effectiveness of this procedure, TAVI is still confined to the treatment of elderly and high-risk patients, because of the newness of the technique, which prevents to make reliable estimation on long-term durability of both available CE mark prostheses. The present multicentre analysis from the Italian registry describes the outcomes of a cohort of TAVI patients with the longest followup using the self- AKI requiring renal replacement therapy, n (%) 4 (2.2) PM implantation, n (%)
22 ( published so far. In addition, this is the first study in which long-term outcomes are defined according to the standardized definitions of the VARC. The 23.6% 12-month mortality in this study compares favourably to other balloon-expandable and self-expanding TAVI clinical reports, including PARTNER trial cohorts A and B and recent national registries, which showed mortality at the same timeframe ranging from 15 to 30. 2 -9 However, the central finding of the present analysis is that 3-year survival after TAVI with the CRS prosthesis amounted to 65%. These data are not surprising, given the baseline risk profile of the subjects undergoing the procedure during the early TAVI experience which was extremely high. Therefore, patients died during follow-up either because of their comorbidities or secondary to conditions associated with advanced age, as proved by the 13% of cardiovascular death rate at 3 years, which mostly occurred during the first month after TAVI, due to procedural complications. This poses an obvious challenge for longer-term real effectiveness of TAVI in such population and raises questions about whether this procedure could improve long-term results in lower-risk patients, as actually suggested by recent reports. 9, 18 According to our findings, since three out of five patients died due to non-cardiovascular reasons at a median of 11 months, almost half of those patients should be denied the procedure in agreement of 2008 European position statement on TAVI, which pointed out that this procedure should not be performed in patients whose life expectancy is ,1 year. 15 Therefore, in the future, it will be crucial to identify patient populations that can derive most advantage from the application of this technology in the perspective of a cost-benefit ratio. Buellesfeld et al. 11 reported data from the CoreValve 'safety and efficacy' study. Survival at 1 and 2 years was 71.9 and 59.7%, respectively; in a further analysis, the authors found that patients classified at high risk before the intervention had twice the risk of major adverse events up to 2 years compared with patients in the moderate-risk group. Although there was no difference in cardiac deaths between the moderate-risk and the high-risk operable groups, there was a significant difference in all-cause mortality due to more non-cardiac events in the high-risk population. Those findings compare favourably with those of our study as stated above about cardiovascular mortality. Compared with the report by Buellesfeld et al., 11 it has to be highlighted the lower incidence of stroke reported in our population (13.5% at 2 years vs. 3.9% at 3 years in the present series). Definitely, the different definitions of stroke between the two studies might strongly affect such comparison. On the other hand, we described a stroke rate which compares favourably with those reported by Gurvitch et al.
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using the VARC definitions. Recently, Gurvitch et al. 10 performed an analysis on long-term (3 years) outcomes and durability of Edwards SAPIEN device; given this aim, patients with unsuccessful procedures or mortality within 30 days were excluded from the analysis because these TAVI: long-term follow-up cases typically reflected procedural complications, rather than issues with the transcatheter valve per se. They showed that TAVI may be accomplished with 81, 74, and 61%, survival at 1, 2, and 3 years, respectively, which is approximately in line with our results. Again, comparisons with the present analysis regarding the incidence of major cardiovascular events (stroke, myocardial infarction, and bleedings) are limited by the heterogeneity of the definitions. Finally, Moat et al. 20 reported 2-year data of the UK-TAVI Registry, which collected data of both self-expanding and balloon-expandable prostheses. Two-year survival was 74%, and the presence of moderate/severe aortic regurgitation, and chronic obstructive pulmonary disease were found the only independent predictors of mortality in a multivariate model. With regards to late morbidity, we found that a percentage slightly higher of 50% was free from serious cardiovascular events, such as death, myocardial infarction, major stroke, and lifethreatening bleeding. As shown in Table 4 , major adverse cardiovascular and cerebrovascular events were primarily contributed by mortality, followed by bleedings. Moreover, almost 14% of patients had hospitalization for cardiac decompensation at followup, and these data are consistent with those reported in PARTNER cohort A trial up to 1 year after TAVI. 3 Interestingly, most of 19 we found that an important part of patients with major vascular complications required red blood cell transfusions; on the other hand, we noted that patients undergoing blood transfusions not had a clear source of bleeding; in such patients, pre-existent anaemia and excessive haemodilution due to fluid administration might be the reason for blood transfusions. Concerning neurologic events, our findings are consistent with previous European registries, 7, 8, 9, 11 but disagree with those reported in PARTNER cohort A, in which almost the 40% of neurologic events occurred from 30 days up to 1 year. 3 Three possible explanations could be hypothesized: first, the higher percentage of preexisting cerebral vascular disease (almost 28%) in the PARTNER population could play a role in the higher incidence of stroke at follow-up; second, in the PARTNER trial 24-Fr devices were used and this technical issue might explain this difference; third, in the randomized trial, the diagnosis of neurological event was made by a specialized neurologist; in this registry, such as in others European registries, cardiologists and anaesthesiologists assessed the neurological function after TAVI, thus possibly leading to an underestimation of all not clinically relevant neurological events. However, our findings underline the importance of further improving the implantation technique with the development of supra-aortic trunks protection devices 25 and with the reduction of delivery catheter profiles in order to reduce the incidence of procedure-related embolic cerebral and bleeding events.
Study limitations
The present study share several important limitations with other observational registries. First, results obtained in a non-randomized fashion were reported, with the lack of comparative arms of patients with severe AS treated by surgery or medical therapy alone. Secondly, the relatively small sample size, even if these data refer to the largest TAVI-CoreValve population with 3-year follow-up published so far. Thirdly, since our data were entered prospectively into a web-based database before the introduction of VARC definitions, re-evaluation of clinical source document relating to clinical events according to the VARC criteria might cause issues with respect to events adjudication; in particular, it may result in the underestimation of the true frequency of some clinically adjudicated events; for that reason, the Steering Committee decided not to report the incidence of minor neurological and bleeding events, which did not undergo independent monitoring or objective assessment. Fourthly, the neurologic events were not adjudicated by a neurologist, probably resulting in the underestimation of the true frequency of such events. Fifthly, echo parameters were not monitored by a central Core-laboratory. Finally, follow-up on echo data and NYHA functional class was performed in a 'survival cohort', with death possibly exerting a competing risk that may have biased our results. Caution therefore must be applied when interpreting these data.
Conclusions
This multicentre study demonstrates that TAVI with the 18-Fr CoreValve ReValving System is associated with sustained clinical and functional cardiovascular benefits in high-risk patients with symptomatic AS up to 3-year follow-up. Non-cardiac causes accounted for the majority of deaths at follow-up.
